Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Class-Wide Rx Safety Issues Are Focus Of FDA Guidance On New Label Change Powers

Executive Summary

FDA is emphasizing a class-based approach to requiring safety-related drug labeling changes under the FDA Amendments Act.
Advertisement

Related Content

FDA Safety Labeling Change Guidance Seeks To Ease Class Confusion
Ribavirin Sponsors Fend Off FDAAA Safety Labeling Changes, For Now
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
With New Power, New Problems: FDA Confronts Complications of Safety Labeling Change Authority
Industry Seeks Power To Trigger Safety Labeling Changes Under FDAAA
Industry Seeks Power To Trigger Safety Labeling Changes Under FDAAA
Safety Labeling Change Order Letters
Safety Labeling Change Order Letters
FDA Draws Upon New Authority To Mandate Elements OF ESA Labeling

Topics

Advertisement
UsernamePublicRestriction

Register

PS053343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel